“As the true prevalence of hypercortisolism and its devastating impact become better understood, physicians are identifying and treating more patients with Cushing’s syndrome than ever before. Our 2023 commercial results reflect strong, nationwide growth in the number of patients receiving Korlym and the number of physicians prescribing the medication. We are confident that rates of screening and treatment will continue to increase. We are providing 2024 revenue guidance of $600 – $630 million,” said Joseph K. Belanoff, CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics price target lowered to $28 from $34 at H.C. Wainwright
- Piper still constructive on Corcept despite patent case ‘disappointing’ outcome
- Corcept Therapeutics says court finds patents not infringed
- Corcept selloff today ‘ideal buying opportunity,’ says Canaccord